Piper Sandler downgraded Q32 Bio (QTTB) to Neutral from Overweight with a price target of $4, down from $20. The firm is surprised by the company’s decision to discontinue complement inhibitor ADX-097 before presenting data from the drug’s renal basket study. The best course of action is to move to Neutral on the name until a better picture of bempikibart’s efficacy profile in alopecia areata emerges, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on QTTB:
- Q32 Bio Restructures to Focus on Bempikibart Development
- Q32 Bio announces corporate restructuring to focus on bempikibart
- Q32 Bio Advances Clinical Trials for Growth Opportunities
- Q32 Bio price target lowered to $22 from $64 at BMO Capital
- Q32 Bio downgraded to Neutral at Guggenheim after failure in atopic dermatitis